New and Notable Clinical Data and Guideline Updates on Systemic Therapies in Hepatocellular Carcinoma
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with hepatocellular carcinoma (HCC).
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
This educational program is intended for medical oncologists, surgical oncologists, pathologists, physician assistants, nurses, pharmacists, and other healthcare professionals who treat patients with HCC.
Upon completion of this activity, participants should be able to:
- Integrate clinical data and consensus guidelines on the use of systemic treatment approaches into practice for patients with early- or intermediate-stage HCC
- Plan evidence-based and guideline-driven individualized care for patients with advanced HCC, both in the frontline and second-line treatment settings
- Select patients who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
- Evaluate the rationale and available data for immune checkpoint inhibitor-based combinations across the continuum of HCC care
- Develop strategies to identify and mitigate unique adverse events associated with novel targeted therapies in patients with HCC
Stacey M. Stein, MD
Associate Professor of Medicine
Division of Medical Oncology
Assistant Medical Director, Clinical Trials Office
Leader, Hepatobiliary Program
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Stacey M. Stein, MD
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
Eisai Inc.: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Merck & Co., Inc.: Consultant/Advisor/Speaker
QED Therapeutics: Consultant/Advisor/Speaker
NCCN and CCO Staff Disclosures
None of the planners/managers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-22-099-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until August 26, 2023. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing